Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow PALI
Palisade Bio, Inc. (PALI) P/E ratio
As of 16 October 2026, Palisade Bio, Inc. (PALI) trades at a P/E ratio of 2.2×. Over the past ten years it has ranged from 0.0× (March 2026) to 36.5× (July 2020); the current reading is higher than 93% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 3.2× | — |
| Mar 2023 | 0.0× | — |
| Dec 2020 | 0.0× | — |
| Sep 2020 | 1.2× | (96.03%) |
| 22 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABEO Abeona Therapeutics Inc. compare | n/m |
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| EYPT EyePoint, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | n/m |
| PALI Palisade Bio, Inc. | 2.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)